Sysmex Inostics

Sysmex Inostics, a subsidiary of Sysmex Corporation, is a molecular diagnostics company that pioneers the use of highly sensitive technologies such as BEAMing (digital PCR) and SafeSEQ (NGS) for mutation detection in cell-free tumor DNA (ctDNA) within the field of oncology. These technologies were initially developed over a decade ago by experts at Johns Hopkins School of Medicine, and this deep expertise in ctDNA analysis lies at the core of Sysmex Inostics’ technical development and implementation capabilities.With more than 10 years of experience in the liquid biopsy field, Sysmex Inostics has become a trusted partner for leading pharmaceutical companies, committed to introducing the most effective personalized cancer therapies to the global market, from discovery to companion diagnostics. Sysmex Inostics' OncoBEAM™ and SafeSEQ services are readily available to support clinical trials and research in oncology. Additionally, OncoBEAM™ provides routine clinical testing through CLIA-certified laboratories, along with distributed kit products across the EU.